$18.24
+0.94%Mirion Technologies, Inc. provides radiation detection, measurement, analysis, and monitoring products and services in the United States, Canada, the United Kingdom, France, Germany, Finland, China, Belgium, Netherlands, Estonia, and Japan. It operates through two segments, Medical and Industrial. The medical segment offers radiation oncology quality assurance and dosimetry solutions; patient safety solutions for diagnostic imaging and radiation therapy centers; radiation therapy quality assurance solutions for calibrating and verifying imaging and treatment accuracy; and radionuclide therapy products for nuclear medicine applications, such as shielding, product handling, medical imaging furniture, and rehabilitation products. This segment supports applications in medical diagnostics, cancer treatment, practitioner safety, and rehabilitation. The Industrial segment focuses on addressing critical radiation safety, measurement, and analysis applications; and provides personal radiation detection, identification equipment, and analysis tools. The company's products and solutions also include nuclear medicines, dosimeters, contamination and clearance monitors, reactor instrumentation and control equipment and systems, medical and industrial imaging systems and related accessories, alpha spectroscopy instruments, alpha/beta counting instruments, and gamma spectroscopy detector systems; and electrical penetration, cancer diagnostics, software, and other services. It serves hospitals, clinics and urgent care facilities, dental and veterinary offices, radiation treatment facilities, OEMs for radiation therapy, laboratories, military organizations, government agencies, industrial companies, power and utility companies, reactor design firms, and NPPs. The company was formerly known as Global Monitoring Systems, Inc. and changed its name to Mirion Technologies, Inc. in January 2006. Mirion Technologies, Inc. was incorporated in 2005 and is headquartered in Atlanta, Georgia.
Strong gross margins indicate healthy pricing and efficient production or service delivery.
Acceptable margins but limited operational leverage. Operating expense control is important.
Minimal profitability after all expenses. Limited financial flexibility for reinvestment or shareholder returns.
Below-average tax rate suggests effective tax planning, favorable jurisdictions, or tax credits.
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
MIR โข NYSE
| Mirion Technologies, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Jun 2018 |
|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||
925.4M | 860.8M | 800.9M | 717.8M | 668.3M | 0.0 | 440.1M | 444.1M | |
GROSS PROFIT | ||||||||
(486.8M) | (459M) | (444.4M) | (400.6M) | (384.1M) | (0.0) | (251.8M) | (275.7M) | |
438.6M | 401.8M | 356.5M | 317.2M | 284.2M | 0.0 | 188.3M | 168.4M | |
OPERATING INCOME | ||||||||
(387.1M) | (377M) | (378.4M) | (615M) | (352.9M) | (2.4M) | (159.5M) | (173.1M) | |
(348.2M) | (338.2M) | (338.6M) | (357.1M) | (267.6M) | (2.4M) | (145.4M) | (153.8M) | |
(38.9M) | (35M) | (31.7M) | (30.3M) | (36.2M) | (0.0) | (14M) | (19.3M) | |
51.5M | 24.8M | -21.9M | -297.8M | -68.7M | -2.4M | 28.8M | -4.7M | |
PRE-TAX INCOME | ||||||||
(42.2M) | (57.9M) | (61.9M) | (42.5M) | (59M) | (0.0) | (0.0) | (0.0) | |
-30.1M | -51.3M | -57.1M | -41.9M | 86.8M | 0.0 | 0.0 | 0.0 | |
(0.0) | (3.8M) | (8.1M) | (227.6M) | (49.1M) | (0.0) | (100K) | (0.0) | |
-18.8M | -58.7M | -83.4M | -8.8M | -159.8M | -43.1M | -155M | -135.8M | |
32.7M | -33.9M | -105.3M | -306.6M | -228.5M | -45.5M | -126.2M | -140.5M | |
NET INCOME | ||||||||
(2.9M) | (2.7M) | -6.6M | -18.2M | -5.1M | -265.9K | -4.2M | -36.8M | |
28.8M | -36.1M | -96.9M | -276.9M | -222.5M | -45.3M | -122M | -103.7M |
MIR - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 14, 2026 | May 13, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | April 29, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 28, 2026 | April 28, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 13, 2026 | April 09, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 01, 2026 | May 13, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 01, 2026 | May 13, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 19, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 10, 2026 | February 10, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 08, 2025 | December 08, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 01, 2025 | December 01, 2025 | 2025 |
Continue your MIR research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.